Author presents five mid-cap long ideas with bull cases, catalysts, and risks: Elastic, Wix, Shift4, American Airlines, and Beam Therapeutics.
ESTC — LONG Author argues Elastic is undervalued after a ~40% derating to ~$65–$74, trading at ~4x FY26 revenue despite 16% growth and 112% net expansion. He sees the Jina AI acquisition and Search AI Lake positioning it as a primary grounding engine for LLMs, with a $500M buyback supporting value. Catalysts include Elastic Cloud consumption trends, adoption of Agent Builder/AI SOC Engine, and FY27 guidance versus the Rule-of-40 target. Main risk is elevated stock-based compensation, negative GAAP profitability, consumption-billing volatility, and competition from Datadog/Splunk.
Stock has derated \~40% from its high to \~$65–$74, now trading at a modest \~4x FY26 revenue despite 16% growth and 112% net expansion.
WIX — LONG Author argues Wix is mispriced because the market is pricing AI commoditization death, yet it trades at a 9–10% FCF yield with 30%+ FCF margins and ~$2B 2025 revenue growing +14%. The bull case hinges on the AI Website Builder improving free-to-paid conversion and Base44 scaling to at least $50M ARR, alongside the Harmony AI rollout into 2026. Main risk is high balance-sheet leverage and aggressive buybacks leaving thin margin for error if AI competitors erode pricing power.
The market is pricing in "AI commoditization" death (shares are down \~61% in the past year), but the financials tell a different story. Trading at a 9–10% FCF yield (\~$5.1B market cap), Wix is a cash machine with 30%+ FCF margins.
FOUR — LONG Author claims Shift4 shows a massive disconnect between price and performance: shares fell ~49% to ~$59 despite 26% volume growth, 50% EBITDA margins, and a $33B backlog. The re-rating depends on converting that backlog, maintaining high-teens organic growth, and executing the Global Blue integration, especially Asia tax-free recovery data. Main risks are high leverage at 4.7x net debt/EBITDA, integration complexity, governance noise around the CEO, and macro softening in consumer travel/dining spend.
A massive disconnect between price and performance. Shares have plummeted \~49% to \~$59 despite 26% volume growth and 50% EBITDA margins. Currently trading at a multiple of \~20x EPS, yet sitting on a $33B backlog ready for installation.
AAL — LONG Author argues American Airlines is undervalued at ~$13.50 after weak 2025 GAAP EPS and weather disruptions, while premium, corporate, and loyalty trends remain solid with loyalty partner cash at $6.1B (+17% YoY) and capacity constraints supporting pricing. Catalysts include Q2 2026 earnings testing 7–10% revenue growth, debt reduction progress toward <$35B, and early AAdvantage/Citi deal uplift. Main risk is a massive debt load at 10.14x net debt/EBITDA, thin interest coverage of 0.95x, and vulnerability to weather events or unhedged fuel costs.
However, premium, corporate, and loyalty trends remain solid: loyalty partner cash reached $6.1B (+17% YoY), AAdvantage accounts and co-brand spend grew mid-single digits, and industry capacity constraints support pricing.
BEAM — LONG Author argues Beam Therapeutics has exceptionally strong clinical data, with risto-cel eliminating vaso-occlusive crises in 31 patients and BEAM-302 showing ~91% protein correction, plus $1.1B cash to reach a 2026 BLA filing. Catalysts include formalizing the risto-cel BLA package in 2026, longer-term BEAM-302 follow-up, and initial BEAM-301 data. Main risk is safety, highlighted by a patient death in the BEACON trial from conditioning toxicity, and a $450M annual burn that could require dilutive financing if regulatory delays occur.
Clinical data for their lead programs is exceptionally strong: risto-cel has eliminated vaso-occlusive crises in 31 patients to date, and BEAM-302 achieved \~91% protein correction in early cohorts. With $1.1B in cash, they have the runway to reach their 2026 BLA filing.